{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:28:36Z","timestamp":1794540516883,"version":"4.9.1"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T00:00:00Z","timestamp":1318982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Anaesthesiol Scand"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Malignant hyperthermia (\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      ) is a potentially fatal complication of general anesthesia triggered by volatile anesthetics. In animal studies, sevoflurane has been reported to be a weak triggering agent. The aim of this study was to evaluate the clinical severity of sevoflurane\u2010induced\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      compared to isoflurane.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From the\n                      <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>\n                      apanese\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      database containing information for 520\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      cases since 1961, we analyzed 147 cases classified by the\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                      linical\n                      <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                      rading\n                      <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>\n                      cale (\n                      <jats:styled-content style=\"fixed-case\">CGS<\/jats:styled-content>\n                      ) as \u2018very likely\u2019 or \u2018almost certain\u2019, accumulated from 1990 to 2009. Sevoflurane without succinylcholine (\n                      <jats:styled-content style=\"fixed-case\">S\u2010SCh<\/jats:styled-content>\n                      (\u2010) group) was given to 48 cases, and isoflurane without succinylcholine (\n                      <jats:styled-content style=\"fixed-case\">I\u2010SCh<\/jats:styled-content>\n                      (\u2010) group) was given to 30. Variables studied were outcome,\n                      <jats:styled-content style=\"fixed-case\">CGS<\/jats:styled-content>\n                      score,\n                      <jats:styled-content style=\"fixed-case\">CGS<\/jats:styled-content>\n                      rank, the first\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      sign, and time from induction to onset of\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      (occurrence time). Clinical signs and maximum laboratory data from six processes of the\n                      <jats:styled-content style=\"fixed-case\">CGS<\/jats:styled-content>\n                      were also analyzed. Each of the\n                      <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>\n                      ann\u2013\n                      <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>\n                      hitney\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>U<\/jats:italic>\n                      <\/jats:styled-content>\n                      \u2010test or the unpaired\n                      <jats:italic>t<\/jats:italic>\n                      \u2010test was used for group comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mortality was 8.3% in the\n                      <jats:styled-content style=\"fixed-case\">S\u2010SCh<\/jats:styled-content>\n                      (\u2010) group and 10.0% in the\n                      <jats:styled-content style=\"fixed-case\">I\u2010SCh<\/jats:styled-content>\n                      (\u2010) group (\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>P<\/jats:italic>\n                      <\/jats:styled-content>\n                      \u2009=\u20090.803). The\n                      <jats:styled-content style=\"fixed-case\">CGS<\/jats:styled-content>\n                      scores were 53.4 (\n                      <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>\n                      , 12.2) and 52.3 (11.7) (\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>P<\/jats:italic>\n                      <\/jats:styled-content>\n                      \u2009=\u20090.691), respectively. The five processes of the\n                      <jats:styled-content style=\"fixed-case\">CGS<\/jats:styled-content>\n                      did not differ between groups. Median occurrence times were 72.5 minutes (range, 36.3\u2013127.5) and 65.0 minutes (30.0\u2013131.3), respectively (\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>P<\/jats:italic>\n                      <\/jats:styled-content>\n                      \u2009=\u20090.890).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      There were no clinically apparent differences between\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      triggered by sevoflurane and isoflurane, and thus no evidence to support the postulate that sevoflurane is a weak or weaker\n                      <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\n                      triggering agent.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1399-6576.2011.02573.x","type":"journal-article","created":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T07:37:13Z","timestamp":1319009833000},"page":"351-356","source":"Crossref","is-referenced-by-count":27,"title":["The severity of sevoflurane\u2010induced malignant hyperthermia"],"prefix":"10.1111","volume":"56","author":[{"given":"T.","family":"MIGITA","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Critical Care Hiroshima University Hospital  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"MUKAIDA","sequence":"additional","affiliation":[{"name":"Division of Anesthesia Hiroshima Prefectural Rehabilitation Center  Higashi\u2010Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"KOBAYASHI","sequence":"additional","affiliation":[{"name":"Division of Anesthesia JA Hiroshima General Hospital  Hatsukaichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"HAMADA","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"KAWAMOTO","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318167aee2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-21"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/85.1.118"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.11.1657"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-10-104"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199907000-00026"},{"key":"e_1_2_6_8_1","first-page":"9","article-title":"Effects of several volatile anesthetics on the Ca2+\u2010related functions of skinned skeletal muscle fibers from the guinea pig","volume":"40","author":"Matsui K","year":"1991","journal-title":"Hiroshima J Med Sci"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199110000-00024"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-006-0495-5"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199404000-00008"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198703000-00006"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/68.2.139"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198503000-00020"},{"key":"e_1_2_6_15_1","first-page":"1611","article-title":"MAC of sevoflurane is 1.71% \u2010Objection to \u2018MAC of sevoflurane as 1.7% is wrong\u2019","volume":"20","author":"Katoh T","year":"1996","journal-title":"Clinical Anesthesia"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-197502000-00014"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005400200026"},{"key":"e_1_2_6_18_1","first-page":"385","article-title":"An analysis of fetal malignant hyperthermia cases after 1990 in Japan (in Japanese)","volume":"20","author":"Maehara Y","year":"2000","journal-title":"Nihon Rinsho Masui Gakkaishi (J Japan Soc Clin Anesth)"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e3181c6b9b2"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.anes.0000265148.86566.68"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2009.03159.x"},{"key":"e_1_2_6_22_1","first-page":"49","volume-title":"Clinical classification and incidence of malignant hyperthermia in Japan. Malignant Hyperthermia: proceeding of the 3rd International symposium on malignant hyperthermia","author":"Yuge O","year":"1994"}],"container-title":["Acta Anaesthesiologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-6576.2011.02573.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-6576.2011.02573.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:28:17Z","timestamp":1698715697000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-6576.2011.02573.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,19]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1399-6576.2011.02573.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-6576.2011.02573.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.721558169.793508673","asserted-by":"object"}]},"ISSN":["0001-5172","1399-6576"],"issn-type":[{"value":"0001-5172","type":"print"},{"value":"1399-6576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,19]]}}}